Principal Investigator: Professor Dong Ki Kim
Department: Seoul National University Hospital, Seoul, South Korea
Collaborating leads –
Dr Yaerim Kim, Keimyung University, Daegu, South Korea
Professor Hyeongsu Kim, Konkuk University, Gwangjin, South Korea
Professor Murim Choi, Seoul National University, Seoul, South Korea
Dr Jin Ho Hwang, Chung-Ang University Hospital, Seoul, South KoreaTags: 53799, cancer, cardiovascular disease, Chronic kidney disease, environment, ethnicity, featured, genetic etiology
Chronic kidney disease (CKD) is a prevalent chronic disease which possesses considerable medical burden as significant portion of CKD patients progress to end-stage renal disease (ESRD) or complicated with various adverse health-related complications. It is pivotal for clinicians to focus on reducing such complications, as cardiovascular disease is the major cause of death among them. Both environmental and genetic factors may contribute to the progression to ESRD or development of adverse complications. Nevertheless, thorough investigations regarding which patients possess the elevated risks had not been evaluated yet. We plan to perform the present study to stratify CKD patients according to the risk of progression to ESRD and the risk of developing adverse outcomes, including cardiovascular events and cancer.
We have undergone several studies using the nationwide data of Korean National Health Insurance System andgovernment-funded prospective cohort dataset called Korean Genome and Epidemiology Study to examine the role of genetic and environmental factors in various chronic diseases.. During the next 36 months with the project using the Biobank data, we aim to demonstrate the potential risk factors which contribute most to the development of health-related complications in CKD patients. Mendelian randomization will be applied to test the causality. Moreover, comparative analysis with Korean cohorts will be performed to evaluate the impact of different environmental and genetic factors on the development of adverse outcomes in CKD patients with different ethnicity and also to determine whether the study results could be adapted worldwide. Consequently, the study results may contribute to the preventive health care to reduce the burden of the chronic disease, through informing clinicians how to distinguish the high-risk patients and to minimize health-related adverse outcomes among the applicable patients.
Project extension – June 2020
Current scope: We aim to investigate the impact of the environmental and genetic factors on the development of health-related adverse outcomes in CKD patients compared to the general population. Numerous environmental and genetic factors may contribute to end-stage renal disease (ESRD) progression or the development of complications; however, consideration of the interaction between the different ethnicity and circumstances had not been deeply evaluated yet. As CKD patients present various clinical courses, it is challenging to identify those with a high risk of developing adverse outcomes. Detecting patients with an elevated risk of complicated health-related outcomes could enable clinicians to appropriately monitor and provide the greatest benefit to suitable patients. Thus, in the present study, we plan to investigate which environmental or genetic factors contribute to the complicated health-related outcomes in CKD patients.
New scope: In the current scope, we aimed to investigate the environmental or genetic risk-factors on clinical outcomes of CKD patients, including ESRD, cardiovascular diseases, cancer, and death, compared to the control group, which was initially defined as the general population with various ethnicity. We plan to additionally expand the study population, especially subdividing the control group. After exploring the environmental and genetic predispositions of the health-related outcomes from the analysis of CKD patients, we plan to test potential risk-factors in the various subgroups; 1) subjects with normal kidney function, 2) subjects with chronic diseases other than CKD and 3) subjects with metabolic syndrome.
Last updated Jun 4, 2020